Thursday, July 9 – Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes rather than intentional misuse. Simple education about proper weekly dosing and gradual dose increases could help prevent many of these avoidable incidents.

Thursday, July 9 – (MedPage Today) — Americans’ use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll.
For patients with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists…

Thursday, July 9 – The new Medicare GLP-1 Bridge program offers broader, more affordable access to weight loss drugs to address the growing obesity crisis. But there’s a catch when it comes to bone health.

Thursday, July 9 – Getting a GLP-1 prescription online can be quick and convenient, but new research suggests it may come with surprisingly little medical oversight. The findings are published in the journal JAMA.

Thursday, July 9 – New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.

Wednesday, July 8 – Survodutide weight-loss drug may reduce harmful fat while preserving muscle

Wednesday, July 8 – AstraZeneca’s new oral GLP-1 pill showed promising results for weight loss and blood sugar in a phase 2 trial. Guido Mieth/Getty Images

A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss in a phase 2b clinical trial.

Experts say GLP-1 drugs in tablet form may encourage more people to take these medications to help treat type 2 diabetes and obesity.

Wednesday, July 8 – A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements for people with type 2 diabetes than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy because it doesn’t require refrigeration or special timing with meals. It’s also cheaper to manufacture, which could expand access globally.

Tuesday, July 7 – Federal regulators have agreed to review a Swiss pharmaceutical company’s applications for two cheaper generic versions of Zepbound and Mounjaro. MK Photo/Alamy Stock Photo

Federal regulators have agreed to review the applications from Swiss pharmaceutical company Sandoz for two cheaper generic versions of the tirzepatide medications Zepbound and Mounjaro.

Tuesday, July 7 – (MedPage Today) — Two-thirds of online GLP-1 receptor agonist sellers did not require speaking with a clinician ahead of a prescription, a secret shopper study revealed.
Out of 49 websites tested, 13 required a video visit and three required…

Tuesday, July 7 – (MedPage Today) — At the American Diabetes Association annual meeting, results from the ACHIEVE-5 trial showed that adding oral orforglipron (Foundayo) to basal insulin significantly improved glycemic control, reduced body weight, and limited…

Tuesday, July 7 – A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren’t often backed by appropriate clinical care.

Tuesday, July 7 – Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk A once-a-day Wegovy weight-loss pill has gone on sale at high street and online pharmacies in the UK, but is not yet available on the NHS.Thousands of people began receiving their first deliveries of the pill, made by the Danish drugmaker Novo Nordisk, on Monday. It contains the same active GLP-1 ingredient as the Wegovy jab, semaglutide, and is similarly effective, according to studies. Continue reading…

Tuesday, July 7 – Option offers once‑daily semaglutide tablets for adults living with obesity

Monday, July 6 – “Obesity will become a disease of poverty.”View Entire Post ›

Monday, July 6 – The once-a-day pill, from the makers of the Wegovy weight-loss jab, can now be bought privately in UK pharmacies.

Saturday, July 4 – A new biweekly GLP-1 injection has been shown to significantly reduce blood sugar in a clinical trial. Image Credit: Hannes P Albert/picture alliance via Getty Images

A new GLP-1 medication demonstrated efficacy in reducing blood sugar in people with type 2 diabetes in a phase 2b clinical trial. 

Bofanglutide is a biweekly (once every 2 weeks) injection compared to once-weekly shots like Ozempic and Wegovy. 

Saturday, July 4 – (MedPage Today) — Popular — and expensive — GLP-1 agonists for weight loss just got a lot cheaper for many older Americans.
Starting this week, the federal government is offering a selection of the brand name medications to certain Medicare…

Friday, July 3 – Semaglutide may lower risk of serious complications in high-risk diabetes

Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or misleading claims about compounded semaglutide, tirzepatide, and, in one case, liraglutide products….By: McDermott Will & Schulte

Friday, July 3 – For decades, it’s been against the law for Medicare to pay for weight-loss medication. But that changed on July 1, with the launch of a new program called Bridge. It gives some people over 65, or who have Medicare for other reasons, access to some weight management medications if they meet certain weight and health criteria.

WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in the…

WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in…

Thursday, July 2 – Individuals with atrial fibrillation (Afib), or irregular heart rhythm, are at increased risk of stroke, chronic kidney disease and heart failure. These risks are significantly exacerbated if a type 2 diabetes diagnosis is added to the mix, says Md Mohaimenul Islam, Ph.D., research assistant professor in the Department of Pharmacy Practice in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.

Thursday, July 2 – (MedPage Today) — Patients with hidradenitis suppurative (HS) and a history of GLP-1 receptor agonist use for diabetes or obesity had significantly lower rates of multiple cardiovascular events and mortality, a large retrospective cohort study…

Thursday, July 2 – A form of fibre that boosts the release of the hunger-reducing hormone GLP-1 has been approved as safe by a European regulator, and could be added to foods within a year

Thursday, July 2 – Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout

Thursday, July 2 – The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans

Thursday, July 2 – Welcome to the “Temu experience of telehealth,” where everyone from Grindr to MAGA influencers can open a virtual clinic selling weight loss drugs and more.

Thursday, July 2 – (MedPage Today) — Incretin-based therapies after bariatric surgery were associated with clinically meaningful augmented weight loss in a dose- and timing-dependent manner, according to U.S. cohort data. (eClinicalMedicine)
A Michigan couple was…

Wednesday, July 1 – Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results.

Wednesday, July 1 – A new pilot program will allow Medicare Part D beneficiaries to access popular weight loss drugs, including Wegovy, Zepbound and Foundayo, at a significantly reduced price for a limited time. NBC News medical contributor Dr. John Torres joins TODAY to break down the details.

Tuesday, June 30 – A growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline/Munro/Getty Images

GLP-1 medications like Ozempic and Wegovy help protect heart health, but stopping the medications may reduce the protective effects.

Some research suggests that GLP-1s containing tirzepatide (Zepbound, Mounjaro) may help lower the risk of further complications in people with cardiovascular disease.

Other research suggests that GLP-1s may help reduce thromboembolic events, such as deep vein thrombosis (DVT), in people with obesity and autoimmune diseases.

Tuesday, June 30 – Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instruction can produce weight loss and blood glucose control in murine models that lasts up to 10 times as long as incretin-mimicking drugs like Ozempic and Wegovy. If shown to be successful in clinical trials, this new method of delivery could eliminate the need for repeated dosing, which currently limits patient access and adherence to these therapies.

Tuesday, June 30 – (MedPage Today) — At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates…

Tuesday, June 30 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may be misused by people with eating disorders. These are serious mental health conditions in which thoughts about food, body weight and body shape become overwhelming, leading to harmful eating behaviors and an intense drive to control food intake. Although concerns about weight or appearance are common, eating disorders go far beyond these everyday worries.

Saturday, June 27 – GLP-1 drugs can provide benefits that may boost an athlete’s performance, but do these medications give them the competitive edge? Getty Images/The Good Brigade

Debates are emerging over whether GLP-1 drugs boost athletic performance.

However, experts say the loss of lean mass associated with using these drugs may cancel out any competitive advantages.

Saturday, June 27 – (MedPage Today) — Use of GLP-1 receptor agonists was associated with a higher risk of smell and taste disturbances among adults with type 2 diabetes, an analysis of electronic health record (EHR) data suggested.
Compared with matched controls…

Saturday, June 27 – “‘Mommy has to take shots to conform to what other people think will look better.'”View Entire Post ›